Ivan Peyron/ISTH
Sep 15, 2025, 17:40
Ivan Peyron Encourages You to Support Resaerch Targeting Rare Coagulation Diseases and Platelet Pathologies
Ivan Peyron, Research Engineer at INSERM, shared on LinkedIn:
Support research!
Bleeding disorders and clotting problems are responsible for many serious illnesses and strokes.
Our mission in the laboratory:
- Deciphering the mechanisms of coagulation
- Understanding diseases like von Willebrand disease and hemophilia
- Improving diagnosis and treatment for patients
Thanks to our innovative nanobody platform (mini-antibodies) developed since 2014, we create:
- Unique tools for research
- Promising therapeutic candidates
Our current projects target rare coagulation diseases and platelet pathologies, to transform patients’ lives.
- By making a donation, you are directly contributing to:
- Better Stroke Prevention
- Improving the management of cardiovascular and inflammatory diseases
- Bringing hope to thousands of patients around the world
Support our research and help us make a difference!”
To support the research, follow the link.
Stay updated on the latest news in the field of clotting disorders with Hemostasis Today.
-
Jun 25, 2026, 19:32Javier M. Floren: A Blood Clot Is One of the Most Impressive Examples of Teamwork You’ll Ever See
-
Jun 25, 2026, 19:31Marcin Krzysztof Maniak: Linking Tissue Mechanics to Inflammation in Health and Disease
-
Jun 25, 2026, 19:29Deepak Rawat: A Diagnosis Like Immune Thrombocytopenia Changes Your Perspective
-
Jun 25, 2026, 19:27Srikanth R.: Don’t Ignore Your Health While Chasing Success
-
Jun 25, 2026, 19:27Jamie Nash: Delighted to Receive the BBTS Race and Sanger Award 2026
-
Jun 25, 2026, 15:56Wolfgang Miesbach: Building the Future of Gene Therapy – From Centre Readiness to Long-Term Patient Care
-
Jun 25, 2026, 15:46Amber Yates: Making a Meaningful Difference for People Living with Sickle Cell Disease
-
Jun 25, 2026, 15:43Nancy Cavey: Navigating Disability Benefits for Patients with Immune Thrombocytopenia
-
Jun 25, 2026, 15:28Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy